PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

The screen behind the scene..., page-2

  1. 333 Posts.
    lightbulb Created with Sketch. 93
    On our path to accelerated approval….

    We patiently await canine study to back up our 2x phase2b trials knowing the objective data from our SAS, NFL and all other content we and others have generated on this amazing molecule is consistent, safe and fills an unmet need.

    Keep turning the screws on the FDA. Eventually they will approve our molecule for use across the globe.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.